OKYO Pharma Ltd is a clinical-stage ophthalmology company focused on developing differentiated therapies for corneal and anterior segment diseases. It is advancing a pipeline designed to improve outcomes for patients suffering from debilitating ocular diseases that impact vision and ocular comfort. The company's main program, urcosimod, is being developed as a potential treatment for neuropathic corneal pain. Additionally, its development pipeline includes an exploratory candidate, OK-201, a non-opioid analgesic drug candidate, as a potential drug to treat acute and chronic ocular pain. The company has only one operating segment: the research and development of biotechnological and pharmaceutical products.
Last trade$1.14
Day change-$0.035 (-2.98%)
Day range$1.12 – $1.21
Volume153,088
Market cap$62M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for OKYO.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for OKYO.
Recent news
Company coverage with links to the original publishers.
OKYO Pharma filed its annual report for fiscal year ended March 31, 2026, announcing a strengthened cash position of $20.6 million following a $22 million capital raise in February 2026. The company is fully funded to complete its NEPTUNE Phase 3 pivotal trial for urcosimod in neuropathic corneal pain, with trial initiation planned for the second half of 2026. The trial will enroll approximately 111 patients and is designed as a potential single-trial registration pathway supported by positive FDA feedback.
OKYO Pharma will present Phase 2 clinical data for urcosimod, its lead candidate for neuropathic corneal pain treatment, at the ASCRS Annual Meeting in Washington, DC on April 11, 2026. The company will also hold a Scientific Advisory Board meeting with leading ophthalmology experts to review data and guide the upcoming Phase 2b/3 trial planned for the first half of 2026. Urcosimod has received FDA Fast Track designation and showed positive efficacy and safety results in the Phase 2 study.
OKYO Pharma Limited announced that Chief Development Officer Gary Jacob acquired 30,980 ordinary shares at $1.59 per share. The company is advancing its flagship drug urcosimod, a ChemR23 agonist, following positive Phase 2a data in neuropathic corneal pain patients. OKYO plans to initiate a Phase 2b/3 trial with approximately 150 subjects in the first half of 2026.
OKYO Pharma announced that its abstract for urcosimod, a novel non-opioid eye-drop therapy for neuropathic corneal pain (NCP), has been accepted for presentation at the ARVO 2026 Annual Meeting in Denver. The Phase 2a clinical trial demonstrated clinically meaningful pain reduction and quality-of-life improvements in NCP patients, with potential to restore corneal nerve structure. The company plans to initiate a larger Phase 2b/3 trial with approximately 150 patients in the first half of 2026.
OKYO Pharma Limited announced a public offering of 10.8 million ordinary shares at $1.85 per share, expected to raise approximately $20 million in gross proceeds (up to $23 million with underwriter option). The company plans to use proceeds for clinical development of its product candidates, including a Phase 2b/3 trial of its flagship drug urcosimod for neuropathic corneal pain. Piper Sandler & Co. is serving as sole manager, with closing expected on February 17, 2026.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.